Table 6Other treatment trials

InterventionAuthor (Year), number of participantsResults
Resource UsePhysicalPsychologicalPhysiologicalQuality of life and general healthDrop-outs/Adverse effectsValidity score
Combination multitreatmentMarlin (1998)210
n=71
Employment status:
Greater number of participants returned to work in treatment group (significance not reported)
49/71 were not followed up. The authors do not report on adverse effects3 (NB controlled trial)
Multitreatment (including supplements)Teitelbaum (2001)215Symptoms, response, fibromyalgia impact qre: significant differences in favour of treatment group (p=0.0002)One patient in each group dropped out because of side effects and one in each group for reasons not reported. 24 reported adverse events in treatment group, 22 in placebo group19
Broad-based managementGoudsmit (1996)211
n=52
Uncertainty, self-efficacy: Improvement in self-efficacy in intervention group compared to control group (p=0.13)

Anxiety and depression: No significant differences between groups.
Symptoms: Significant improvement in intervention groups compared to control group in fatigue (p=0.03) and somatic symptoms (p=0.04).
No significant differences between groups for cognitive difficulty.

Functional impairment: No significant differences between groups.

Coping: No significant differences between groups.
Eight excluded from analysis: 3 in intervention group and 5 controls. Two wishes to discontinue treatment: not stated from which group.

9% of intervention group and 18% of controls ‘felt worse’ at the end of the study.
3 (NB controlled trial) [Revised validity after guidelines stakeholder consultation]
Buddy/mentor programmeSchlaes (1996)212
n=12
Fatigue severity: greater improvement in treatment group compared to control (p<0.03)Positive thinking,, depression, psychological distress, perceived stress, coping strategies, perceived social support: no significant differences between groups2 dropped out, one in each group, could not complete post-test measures due to severity of illness.4 (NB controlled trial)
Group therapySoderberg (2001)213
n=14
Fatigue: results not reportedQuality of life: comparisons were not made between groupsOne withdrawal in control group1
Low sugar low yeast dietHobday (2005, unpublished)214
n=57
Fatigue: no significant differences between groupsAnxiety, depression: no significant differences between groupsGeneral health: no significant differences between groups8 in the LSLY arm and 9 in the control arm were lost to follow-up11

Results in bold indicate statistically significant differences between treatment groups (p<0.05)

From: Appendix 1, Systematic Evidence Review to support the development of the NICE clinical guideline for CFS/ME in adults and children

Cover of Chronic Fatigue Syndrome/Myalgic Encephalomyelitis (or Encephalopathy)
Chronic Fatigue Syndrome/Myalgic Encephalomyelitis (or Encephalopathy): Diagnosis and Management of Chronic Fatigue Syndrome/Myalgic Encephalomyelitis (or Encephalopathy) in Adults and Children [Internet].
NICE Clinical Guidelines, No. 53.
National Collaborating Centre for Primary Care (UK).
Copyright © 2007, Royal College of General Practitioners.

PubMed Health. A service of the National Library of Medicine, National Institutes of Health.